{"nctId":"NCT00105183","briefTitle":"EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection","startDateStruct":{"date":"2005-01"},"conditions":["Chronic Obstructive Pulmonary","Idiopathic Pulmonary Fibrosis","Cystic Fibrosis","Bronchiectasis","Pulmonary Vascular Disease"],"count":223,"armGroups":[{"label":"EZ-2053","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: EZ-2053"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]},{"label":"EZ-2053 5mg/kg","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: EZ-2053 5mg/kg"]}],"interventions":[{"name":"Placebo","otherNames":["Saline"]},{"name":"EZ-2053","otherNames":["ATG","Anti-human-T-Lymphocyte Immune Globulin, Rabbit"]},{"name":"EZ-2053 5mg/kg","otherNames":["ATG","Anti-human-T-Lymphocyte Immune Globulin, Rabbit"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Recipient of a primary single or double pulmonary allograft\n* Capable of understanding the purposes and risks of the study and has given written informed consent, and agrees to comply with the study requirements\n* Women of childbearing potential must have a negative serum pregnancy test within 4 days prior to randomization.\n\nExclusion Criteria:\n\n* Undergoing second or living donor transplant\n* Prior treatment with T-cell depleting agents within the previous 5 years for the purpose of immunosuppression\n* Prior plasma exchange and/or treatment with IVIg within the past 5 years\n* Pulmonary infection with pan-resistant Pseudomonas or any Burkholderia species\n* Known positive blood cultures\n* Donor lung ischemia time \\> 8 hours for first lung and \\> 8 hours for the second lung\n* Previously received or is receiving a multi-organ transplant\n* Pregnant women, nursing mothers or women of child-bearing potential who are unwilling to use reliable contraception. Effective contraception must be used BEFORE beginning study drug therapy, for the duration of the study and for 6 months following completion of the study\n* Active, extra-pulmonary systemic infection requiring the prolonged or chronic use of antimicrobial agents or the presence of a chronic active hepatitis B or C\n* Active liver disease (liver function tests greater than or equal to 2 times the upper limit of normal)\n* Severe anemia (hemoglobin, \\< 6 g/dL), leukopenia (WBC \\< 2500/mm3), thrombocytopenia (platelet count \\< 80,000/mm3), polycythemia (Hct \\> 54% \\[male\\], Hct \\> 49% \\[female\\]) or clinically significant coagulopathy\n* Recipient or donor is seropositive for HIV\n* Previous exposure or known contraindication to administration of the study drug or to rabbit proteins\n* Current malignancy or a history of malignancy (within the previous 5 years), except non-metastatic basal cell or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix that has been treated successfully\n* Unstable cardiovascular disease, or a myocardial infarction within the previous 6 months\n* Currently participating in another clinical trial with an investigational agent and/or is taking or has been taking an investigational agent in the 30 days prior to transplant and/or has not recovered from any reversible side effects of prior investigational drug\n* Unlikely to comply with visits schedule in the protocol\n* Any current history of substance abuse, psychiatric disorder or a condition that, in the opinion of the Investigator, may invalidate communication with the Investigator.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With the Event Death, Graft Loss, Acute Rejection and/or Loss to Follow-up (Whichever Occurred First)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Death or Graft Loss Post-transplant","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Acute Rejection","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Infections and Infestations","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Severe Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Pulmonary Function Tests, Total Distance Walked 6 Minute Walk Test","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"457.0","spread":null},{"groupId":"OG001","value":"448.0","spread":null},{"groupId":"OG002","value":"427.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Pulmonary Function Test, Forced Vital Capacity","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"2.9","spread":null},{"groupId":"OG002","value":"3.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Pulmonary Function Test, Forced Expiratory Volume in 1 Second","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"2.3","spread":null},{"groupId":"OG002","value":"2.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Pulmonary Function Test, Forced Expiratory Flow 25-75","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"2.2","spread":null},{"groupId":"OG002","value":"2.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":65,"n":82},"commonTop":["Nausea","Anaemia","Pleural effusion","Oedema peripheral","Diarrhoea"]}}}